Drugs / BRII-835
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06650852 | Oct 2024 → Jul 2026 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06491563 | Aug 2024 → Dec 2026 expected | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05970289 | Aug 2023 → Jul 2025 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650852 ↗ |
| Known as | VIR-2218 | “BRII-835 (VIR-2218)” NCT06650852 ↗1“BRII-835 (VIR-2218)” NCT06491563 ↗ |
| Route | Subcutaneous | “BRII-835 will be given via subcutaneous injection” NCT05970289 ↗ |